Fanny Wunder

663 total citations
10 papers, 20 citations indexed

About

Fanny Wunder is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Fanny Wunder has authored 10 papers receiving a total of 20 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Fanny Wunder's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Fanny Wunder is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Fanny Wunder collaborates with scholars based in United States, France and Spain. Fanny Wunder's co-authors include Enriqueta Felip, Pierre Saintigny, Richard L. Schilsky, Jacques Raynaud, Razelle Kurzrock, Vladimir Lazar, Amir Onn, Eitan Rubin, Catherine Bresson and Cristian Moldovan and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Oncotarget.

In The Last Decade

Fanny Wunder

7 papers receiving 19 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fanny Wunder United States 3 10 10 8 8 4 10 20
Rajesh Gottimukkala United States 2 7 0.7× 12 1.2× 11 1.4× 14 1.8× 3 0.8× 4 28
Guowu Wu China 3 8 0.8× 5 0.5× 13 1.6× 14 1.8× 4 1.0× 8 26
B Sheu United States 2 11 1.1× 11 1.1× 11 1.4× 9 1.1× 2 0.5× 2 25
Mariah Malak Bilalaga United States 2 5 0.5× 7 0.7× 10 1.3× 7 0.9× 4 1.0× 4 18
Julia E. Rudolph United States 4 7 0.7× 7 0.7× 10 1.3× 6 0.8× 2 0.5× 7 22
Dana R. Valley United States 3 7 0.7× 10 1.0× 12 1.5× 7 0.9× 3 0.8× 3 25
J. Maxwell Douglas Canada 3 8 0.8× 12 1.2× 10 1.3× 11 1.4× 5 1.3× 3 29
Hollie Bancroft United Kingdom 2 13 1.3× 17 1.7× 7 0.9× 10 1.3× 2 0.5× 3 24
Gloryanne Aidoo-Micah United Kingdom 3 7 0.7× 6 0.6× 12 1.5× 9 1.1× 2 0.5× 4 25
Elen Höglander United Kingdom 4 10 1.0× 9 0.9× 13 1.6× 19 2.4× 6 1.5× 5 32

Countries citing papers authored by Fanny Wunder

Since Specialization
Citations

This map shows the geographic impact of Fanny Wunder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fanny Wunder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fanny Wunder more than expected).

Fields of papers citing papers by Fanny Wunder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fanny Wunder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fanny Wunder. The network helps show where Fanny Wunder may publish in the future.

Co-authorship network of co-authors of Fanny Wunder

This figure shows the co-authorship network connecting the top 25 collaborators of Fanny Wunder. A scholar is included among the top collaborators of Fanny Wunder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fanny Wunder. Fanny Wunder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Landau, Ofer, Catherine Bresson, Fanny Wunder, et al.. (2025). OncoAID: an open access targeted anti-cancer drugs database. Frontiers in Pharmacology. 16. 1588191–1588191.
2.
Kurzrock, Razelle, N. Saoudi Gonzalez, Catherine Bresson, et al.. (2025). Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment. Oncotarget. 16(1). 456–466.
3.
Lazar, Vladimir, Éric Raymond, Catherine Bresson, et al.. (2024). Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors. Therapeutic Advances in Medical Oncology. 16. 12733936–12733936.
4.
Lazar, Vladimir, Baolin Zhang, Christophe Le Tourneau, et al.. (2023). A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. Therapeutic Advances in Medical Oncology. 15. 2601118–2601118. 7 indexed citations
5.
6.
7.
Rodón, Jordi, Jean‐Charles Soria, Raanan Berger, et al.. (2018). WINTHER: An international WIN Consortium precision medicine trial using genomic and transcriptomic analysis in patients with advanced malignancies.. Journal of Clinical Oncology. 36(15_suppl). 12011–12011. 5 indexed citations
8.
Soria, Jean‐Charles, Jordi Rodón, Raanan Berger, et al.. (2017). WINTHER: An international study to select rational therapeutics based on the analysis of matched tumor and normal biopsies in subjects with advanced malignancies.. Journal of Clinical Oncology. 35(15_suppl). TPS11625–TPS11625. 1 indexed citations
9.
Martineau, Géraldine, Agnès Laplanche, Gedske Daugaard, et al.. (2014). GEFCAPI 04: A phase III trial comparing a treatment oriented by a molecular analysis with CancerTYPE ID test to cisplatin-gemcitabine in patients with carcinoma of an unknown primary (CUP).. Journal of Clinical Oncology. 32(15_suppl). TPS11134–TPS11134. 1 indexed citations
10.
Planchard, David, Fabrice Barlési, Julien Mazières, et al.. (2014). Phase I Study of Tremelimumab (Trem) in Combination with Gefitinib (Gef) in Epidermal Growth Factor Receptor Mutant (Egfr-Mut) Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology. 25. iv468–iv468. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rajesh Gottimukkala Breakdown of academic impact, for papers by Guowu Wu Breakdown of academic impact, for papers by B Sheu Breakdown of academic impact, for papers by Mariah Malak Bilalaga Breakdown of academic impact, for papers by Julia E. Rudolph Breakdown of academic impact, for papers by Dana R. Valley Breakdown of academic impact, for papers by J. Maxwell Douglas Breakdown of academic impact, for papers by Hollie Bancroft Breakdown of academic impact, for papers by Gloryanne Aidoo-Micah Breakdown of academic impact, for papers by Elen Höglander
Rankless by CCL
2026